1. Home
  2. DVAX vs FINW Comparison

DVAX vs FINW Comparison

Compare DVAX & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$15.55

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo FinWise Bancorp

FINW

FinWise Bancorp

HOLD

Current Price

$18.00

Market Cap

245.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
DVAX
FINW
Founded
1996
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
245.2M
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
DVAX
FINW
Price
$15.55
$18.00
Analyst Decision
Hold
Buy
Analyst Count
5
2
Target Price
$26.50
$22.00
AVG Volume (30 Days)
5.6M
21.3K
Earning Date
02-19-2026
01-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.05
Revenue
$330,514,000.00
$80,198,000.00
Revenue This Year
$24.63
$83.64
Revenue Next Year
$15.85
$38.08
P/E Ratio
N/A
$17.28
Revenue Growth
26.73
14.76
52 Week Low
$9.20
$13.49
52 Week High
$15.73
$22.49

Technical Indicators

Market Signals
Indicator
DVAX
FINW
Relative Strength Index (RSI) 80.02 53.72
Support Level $15.56 $17.75
Resistance Level $15.73 $17.87
Average True Range (ATR) 0.08 0.34
MACD -0.14 0.09
Stochastic Oscillator 48.61 55.39

Price Performance

Historical Comparison
DVAX
FINW

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

Share on Social Networks: